Rod-cone dystrophy (RCD) is a group of inherited retinal disorders characterized by the progressive degeneration of the light-sensitive cells in the eye, known as photoreceptors. The human retina contains two main types of photoreceptors: rods, which are responsible for vision in low light and peripheral vision, and cones, which handle color vision and central visual acuity. In rod-cone dystrophy, the rod cells are affected first and most severely, followed by the subsequent degeneration of cone cells.
This condition is often used interchangeably with retinitis pigmentosa (RP), which is the most common form of rod-cone dystrophy. The initial symptom for most patients is nyctalopia, or night blindness, which often manifests in childhood or early adolescence. Individuals may find it increasingly difficult to navigate in dimly lit environments or adjust to sudden changes in lighting. As the disease progresses, patients typically experience a gradual loss of peripheral vision, often described as "tunnel vision."
In the later stages of rod-cone dystrophy, the degeneration extends to the cone cells, which can lead to a decline in central vision, color perception, and the ability to read or recognize faces. The rate of progression and the severity of vision loss can vary significantly from person to person, even among family members with the same genetic mutation.
Diagnosis usually involves a comprehensive eye examination, including visual field testing, optical coherence tomography (OCT) to assess retinal structure, and electroretinography (ERG) to measure the electrical activity of the photoreceptors. While receiving a diagnosis of rod-cone dystrophy can be overwhelming, understanding the condition is the first step in managing its impact. Patients are strongly encouraged to consult their healthcare provider or a retinal specialist to discuss their specific diagnosis, monitor disease progression, and explore available supportive strategies.